| Role |
Name |
Disclosure |
Details |
| Author | Gus Gonzalez, MD, Medical Oncologist, Department of Hematology/Oncology, Sparks Regional Medical Center | Nothing to disclose | Details | | Coauthor | E Randy Eichner, MD, Professor, Department of Internal Medicine, University of Oklahoma Health Sciences Center | Nothing to disclose | Details | | Medical Editor | Paul Schick, MD, Emeritus Professor, Department of Internal Medicine, Thomas Jefferson University Medical College; Research Professor, Department of Internal Medicine, Drexel University College of Medicine | Nothing to disclose | Details | | Pharmacy Editor | Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine | Nothing to disclose | Details | | Managing Editor | Ronald A Sacher, MB, BCh, MD, FRCPC, Director of the Hoxworth Blood Center, Professor, Departments of Internal Medicine and Pathology, University of Cincinnati Medical Center | Glaxo Smith Kline Talecris | Details | | CME Editor | Rajalaxmi McKenna, MD, FACP, Consulting Staff, Department of Medicine, Southwest Medical Consultants, SC, Good Samaritan Hospital, Advocate Health Systems | Nothing to disclose | Details | | Chief Editor | Emmanuel C Besa, MD, Professor, Department of Medicine, Division of Hematologic Malignancies, Kimmel Cancer Center, Thomas Jefferson University | Nothing to disclose | Details |
Contributor Disclosure
Contributor:
|
Contributor Disclosure: |
| Gus Gonzalez, Author |
The contributor discloses no conflict of interest. |
Contributor Disclosure
Contributor:
|
Contributor Disclosure: |
| E Randy Eichner, Coauthor |
The contributor discloses no conflict of interest. |
|